The use of next generation sequencing for clinical applications is growing rapidly and the use of Next Generation Sequencing (NGS) panels is, in some areas, becoming standard of care. While panels can be highly informative from a broad perspective, it is not guaranteed that the particular SNP or insertion\/ deletion of interest will be present. When a specific targeted therapy is under evaluation and a single gene is of primary interest, there is a strong rationale for developing a NGS assay specifically for that gene.<\/p>\n\n\n\n
In this webinar, Almac\u2019s Head of Laboratory Operations Dr. Leeona Galligan presents details on the development and implementation of a clinical NGS assay for TP53 which is being used routinely for clinical trial stratification.<\/p>\n\n\n\n
The webinar is now available on demand should you wish to view or share with a colleague. To instantly access the webinar please submit the form below.<\/p>\n\n\n\n","protected":false},"featured_media":0,"template":"","diagnostics_type":[474],"class_list":["post-1092","diagnostic_resource","type-diagnostic_resource","status-publish","hentry","diagnostics_type-diagnostics-webinars"],"acf":[],"yoast_head":"\n